About

Medicines have the power to transform people's lives. Yet despite remarkable advances in pharmaceutical science, many diseases still lack effective treatments, and countless biological targets remain beyond the reach of conventional drug discovery.
At PRISM BioLab, we are committed to addressing this challenge by pursuing a new way of drug discovery, built on our proprietary PepMetics® technology.
There is no established roadmap for creating something truly new. Every step forward presents unknown challenges. We believe that progress comes only by confronting each challenge, formulating hypotheses, testing them rigorously, learning from failure, and continuing to move forward. To us, this is the very essence of science.
A new way of drug discovery is an extraordinarily complex endeavor. Breakthrough innovation can only be achieved when scientists from diverse disciplines respect each other's expertise and combine their knowledge and experience.
That is why, above all else, we value the scientists who create and advance our technology. We strive to build an environment where researchers are free to think creatively, embrace new challenges, and devote themselves to science while keeping in mind the patients whose lives may ultimately be changed by their work. We believe that this is the driving force behind creating medicines that make a global impact.
Japan is home to many outstanding scientists. At the same time, the global pharmaceutical industry is led by companies with immense research and development resources. For a small biotechnology company to have a meaningful role on the world stage, it must take on challenges that no one else can and create technologies with strengths that no one else can match.
PepMetics® is the proprietary platform that supports this ambition. By continuously improving our technology and collaborating with pharmaceutical companies and biotechnology innovators around the world, we are advancing the new way of drug discovery and striving to realize a future where everyone can live a life filled with hope.

Since our IPO, our drug discovery platform has continued to evolve, and multiple collaborative research programs have also steadily advanced. Our internal discovery programs have generated numerous promising hit compounds against targets that have been considered difficult for conventional small-molecule drug discovery. These achievements demonstrate that PepMetics® has evolved beyond a promising concept into a drug discovery platform capable of continuously generating innovative and differentiated therapeutic candidates.

Our efforts in developing this new way of drug discovery are now yielding fruit. With the dedicated effort of our scientists and continued support from our investors we will create medicines that transform people’s lives.

We sincerely appreciate your continued understanding and support.